{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T05:54:15Z","timestamp":1787205255527,"version":"build-2736575974"},"reference-count":51,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,3,14]],"date-time":"2022-03-14T00:00:00Z","timestamp":1647216000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011531","name":"University of Alabama","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011531","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001545","name":"Children's Tumor Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001545","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["P30 DK074038"],"award-info":[{"award-number":["P30 DK074038"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["P60 DK079626"],"award-info":[{"award-number":["P60 DK079626"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy - Nucleic Acids"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1016\/j.omtn.2022.03.011","type":"journal-article","created":{"date-parts":[[2022,3,14]],"date-time":"2022-03-14T23:08:28Z","timestamp":1647299308000},"page":"261-278","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"special_numbering":"C","title":["Targeted exon skipping of NF1 exon 17 as a therapeutic for neurofibromatosis type I"],"prefix":"10.1016","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2647-2693","authenticated-orcid":false,"given":"Andr\u00e9","family":"Leier","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Moore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Daniel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexis M.","family":"Hyde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ludwine","family":"Messiaen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce R.","family":"Korf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0778-7195","authenticated-orcid":false,"given":"Jamuna","family":"Selvakumaran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lukasz","family":"Ciszewski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Lambert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6621-6096","authenticated-orcid":false,"given":"Jeremy","family":"Foote","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret R.","family":"Wallace","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1331-0780","authenticated-orcid":false,"given":"Robert A.","family":"Kesterson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Dickson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"Popplewell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8217-0892","authenticated-orcid":false,"given":"Deeann","family":"Wallis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.omtn.2022.03.011_bib1","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/0896-6273(93)90324-K","article-title":"The neurofibromatosis type 1 gene and its protein product, neurofibromin","volume":"10","author":"Gutmann","year":"1993","journal-title":"Neuron"},{"key":"10.1016\/j.omtn.2022.03.011_bib2","series-title":"Neurofibromatosis: Phenotype, Natural History, and Pathogenesis","author":"Friedman","year":"1999"},{"key":"10.1016\/j.omtn.2022.03.011_bib3","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1038\/gim.2017.215","article-title":"Prevalence of neurofibromatosis type 1 in the Finnish population","volume":"20","author":"Kallionp\u00e4\u00e4","year":"2018","journal-title":"Genet. Med."},{"key":"10.1016\/j.omtn.2022.03.011_bib4","doi-asserted-by":"crossref","first-page":"2550","DOI":"10.1056\/NEJMoa1605943","article-title":"Activity of selumetinib in neurofibromatosis type 1-related plexiform neurofibromas","volume":"375","author":"Dombi","year":"2016","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.omtn.2022.03.011_bib5","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1089\/nat.2013.0461","article-title":"Exon-skipping antisense oligonucleotides to correct missplicing in neurogenetic diseases","volume":"24","author":"Siva","year":"2014","journal-title":"Nucleic Acid Ther."},{"key":"10.1016\/j.omtn.2022.03.011_bib6","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1517\/14712598.2014.866087","article-title":"New developments in the use of gene therapy to treat Duchenne muscular dystrophy","volume":"14","author":"Jarmin","year":"2014","journal-title":"Expert Opin. Biol. Ther."},{"key":"10.1016\/j.omtn.2022.03.011_bib7","series-title":"FDA Grants Accelerated Approval to First Drug for Duchenne Muscular Dystrophy","author":"Walsh","year":"2016"},{"key":"10.1016\/j.omtn.2022.03.011_bib8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1089\/nat.2016.0657","article-title":"FDA approves eteplirsen for Duchenne muscular dystrophy: the next chapter in the eteplirsen saga","volume":"27","author":"Aartsma-Rus","year":"2017","journal-title":"Nucleic Acid Ther."},{"key":"10.1016\/j.omtn.2022.03.011_bib9","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1089\/nat.2020.0845","article-title":"The 10th oligonucleotide therapy approved: golodirsen for Duchenne muscular dystrophy","volume":"30","author":"Aartsma-Rus","year":"2020","journal-title":"Nucleic Acid Ther."},{"key":"10.1016\/j.omtn.2022.03.011_bib10","doi-asserted-by":"crossref","first-page":"e169","DOI":"10.1212\/NXG.0000000000000169","article-title":"Updated nomenclature for human and mouse neurofibromatosis type 1 genes","volume":"3","author":"Anastasaki","year":"2017","journal-title":"Neurol. Genet."},{"key":"10.1016\/j.omtn.2022.03.011_bib11","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/S0014-5793(03)01507-2","article-title":"PKA phosphorylation and 14-3-3 interaction regulate the function of neurofibromatosis type I tumor suppressor, neurofibromin","volume":"557","author":"Feng","year":"2004","journal-title":"FEBS Lett."},{"key":"10.1016\/j.omtn.2022.03.011_bib12","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1126\/science.1176615","article-title":"Cell-specific information processing in segregating populations of Eph receptor ephrin-expressing cells","volume":"326","author":"J\u00f8rgensen","year":"2009","journal-title":"Science"},{"key":"10.1016\/j.omtn.2022.03.011_bib13","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1042\/BST20160172","article-title":"The contribution of intrinsically disordered regions to protein function, cellular complexity, and human disease","volume":"44","author":"Babu","year":"2016","journal-title":"Biochem. Soc. Trans."},{"key":"10.1016\/j.omtn.2022.03.011_bib14","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1126\/science.277.5324.333","article-title":"The Ras-RasGAP complex: structural basis for GTPase activation and its loss in oncogenic Ras mutants","volume":"277","author":"Scheffzek","year":"1997","journal-title":"Science"},{"key":"10.1016\/j.omtn.2022.03.011_bib15","series-title":"Neurofibromatosis Type 1: Molecular and Cellular Biology","first-page":"305","article-title":"Neurofibromin: protein domains and functional characteristics","author":"Scheffzek","year":"2012"},{"key":"10.1016\/j.omtn.2022.03.011_bib16","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/S0014-5793(04)00078-X","article-title":"Neurofibromin is actively transported to the nucleus","volume":"560","author":"Vandenbroucke","year":"2004","journal-title":"FEBS Lett."},{"key":"10.1016\/j.omtn.2022.03.011_bib17","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/gim.2015.30","article-title":"Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American college of medical genetics and genomics and the association for molecular pathology","volume":"17","author":"Richards","year":"2015","journal-title":"Genet. Med."},{"key":"10.1016\/j.omtn.2022.03.011_bib18","first-page":"759","article-title":"Mice with missense and nonsense NF1 mutations display divergent phenotypes compared with human neurofibromatosis type I","volume":"9","author":"Li","year":"2016","journal-title":"Dis. Model. Mech."},{"key":"10.1016\/j.omtn.2022.03.011_bib19","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1093\/hmg\/ddw039","article-title":"NF1 germline mutation differentially dictates optic glioma formation and growth in neurofibromatosis-1","volume":"25","author":"Toonen","year":"2016","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.omtn.2022.03.011_bib20","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1002\/humu.21500","article-title":"A mild neurofibromatosis type 1 phenotype produced by the combination of the benign nature of a leaky NF1-splice mutation and the presence of a complex mosaicism","volume":"32","author":"Fern\u00e1ndez-Rodr\u00edguez","year":"2011","journal-title":"Hum. Mutat."},{"key":"10.1016\/j.omtn.2022.03.011_bib21","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1002\/humu.20933","article-title":"Antisense therapeutics for neurofibromatosis type 1 caused by deep intronic mutations","volume":"30","author":"Pros","year":"2009","journal-title":"Hum. Mutat."},{"key":"10.1016\/j.omtn.2022.03.011_bib22","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1002\/humu.23421","article-title":"Neurofibromin (NF1) genetic variant structure-function analyses using a full-length mouse cDNA","volume":"39","author":"Wallis","year":"2018","journal-title":"Hum. Mutat."},{"key":"10.1016\/j.omtn.2022.03.011_bib23","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1002\/humu.24290","article-title":"Analysis of patient-specific NF1 variants leads to functional insights for Ras signaling that can impact personalized medicine","volume":"43","author":"Long","year":"2022","journal-title":"Hum. Mutat."},{"key":"10.1016\/j.omtn.2022.03.011_bib24","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.ccell.2020.02.003","article-title":"Neurofibromin is an estrogen receptor-alpha transcriptional Co-repressor in breast cancer","volume":"37","author":"Zheng","year":"2020","journal-title":"Cancer Cell"},{"key":"10.1016\/j.omtn.2022.03.011_bib25","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1038\/s41434-020-0156-6","article-title":"Optimization of antisense-mediated exon skipping for Duchenne muscular dystrophy","volume":"27","author":"Dzierlega","year":"2020","journal-title":"Gene Ther."},{"key":"10.1016\/j.omtn.2022.03.011_bib26","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.1016\/j.ymthe.2017.07.014","article-title":"Quantitative antisense screening and optimization for exon 51 skipping in Duchenne muscular dystrophy","volume":"25","author":"Echigoya","year":"2017","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtn.2022.03.011_bib27","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1038\/mt.2010.212","article-title":"Antisense-induced myostatin exon skipping leads to muscle hypertrophy in mice following octa-guanidine morpholino oligomer treatment","volume":"19","author":"Kang","year":"2011","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtn.2022.03.011_bib28","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/mt.2010.261","article-title":"Chronic systemic therapy with low-dose morpholino oligomers ameliorates the pathology and normalizes locomotor behavior in mdx mice","volume":"19","author":"Malerba","year":"2011","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtn.2022.03.011_bib29","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1126\/science.1104297","article-title":"Rescue of dystrophic muscle through U7 snRNA-mediated exon skipping","volume":"306","author":"Goyenvalle","year":"2004","journal-title":"Science"},{"key":"10.1016\/j.omtn.2022.03.011_bib30","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1038\/mt.2012.26","article-title":"Engineering multiple U7snRNA constructs to induce single and multiexon-skipping for Duchenne muscular dystrophy","volume":"20","author":"Goyenvalle","year":"2012","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtn.2022.03.011_bib31","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1016\/j.omtm.2020.04.025","article-title":"Long-term efficacy of AAV9-U7snRNA-mediated exon 51 skipping in mdx52 mice","volume":"17","author":"Aupy","year":"2020","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.omtn.2022.03.011_bib32","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1002\/jcsm.12542","article-title":"Myostatin inhibition in combination with antisense oligonucleotide therapy improves outcomes in spinal muscular atrophy","volume":"11","author":"Zhou","year":"2020","journal-title":"J.\u00a0Cachexia Sarcopenia Muscle"},{"key":"10.1016\/j.omtn.2022.03.011_bib33","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1056\/NEJMoa1702752","article-title":"Nusinersen versus sham control in infantile-onset spinal muscular atrophy","volume":"377","author":"Finkel","year":"2017","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.omtn.2022.03.011_bib34","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1056\/NEJMoa1710504","article-title":"Nusinersen versus sham control in later-onset spinal muscular atrophy","volume":"378","author":"Mercuri","year":"2018","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.omtn.2022.03.011_bib35","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1038\/ng0794-353","article-title":"Tumour predisposition in mice heterozygous for a targeted mutation in Nf1","volume":"7","author":"Jacks","year":"1994","journal-title":"Nat. Genet."},{"key":"10.1016\/j.omtn.2022.03.011_bib36","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/86898","article-title":"Learning deficits, but normal development and tumor predisposition, in mice lacking exon 23a of Nf1","volume":"27","author":"Costa","year":"2001","journal-title":"Nat. Genet."},{"key":"10.1016\/j.omtn.2022.03.011_bib37","first-page":"487","article-title":"A conserved alternative splice in the von Recklinghausen neurofibromatosis (NF1) gene produces two neurofibromin isoforms, both of which have GTPase-activating protein activity","volume":"13","author":"Andersen","year":"1993","journal-title":"Mol. Cell Biol."},{"key":"10.1016\/j.omtn.2022.03.011_bib38","doi-asserted-by":"crossref","first-page":"W337","DOI":"10.1093\/nar\/gku366","article-title":"PredictProtein--an open resource for online prediction of protein structural and functional features","volume":"42","author":"Yachdav","year":"2014","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.omtn.2022.03.011_bib39","doi-asserted-by":"crossref","first-page":"W344","DOI":"10.1093\/nar\/gkw408","article-title":"ConSurf 2016: an improved methodology to estimate and visualize evolutionary conservation in macromolecules","volume":"44","author":"Ashkenazy","year":"2016","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.omtn.2022.03.011_bib40","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1093\/bib\/3.3.265","article-title":"PROSITE: a documented database using patterns and profiles as motif descriptors","volume":"3","author":"Sigrist","year":"2002","journal-title":"Brief Bioinform"},{"key":"10.1016\/j.omtn.2022.03.011_bib41","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1016\/j.bbapap.2013.04.006","article-title":"hCKSAAP_UbSite: improved prediction of human ubiquitination sites by exploiting amino acid pattern and properties","volume":"1834","author":"Chen","year":"2013","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.omtn.2022.03.011_bib42","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1093\/bioinformatics\/btt196","article-title":"Incorporating key position and amino acid residue features to identify general and species-specific Ubiquitin conjugation sites","volume":"29","author":"Chen","year":"2013","journal-title":"Bioinformatics"},{"key":"10.1016\/j.omtn.2022.03.011_bib43","doi-asserted-by":"crossref","first-page":"3124","DOI":"10.1074\/jbc.M115.703710","article-title":"Interaction between a domain of the negative regulator of the Ras-ERK pathway, SPRED1 protein, and the GTPase-activating protein-related domain of neurofibromin is implicated in legius syndrome and neurofibromatosis type 1","volume":"291","author":"Hirata","year":"2016","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.omtn.2022.03.011_bib44","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1038\/mt.2008.287","article-title":"Design of phosphorodiamidate morpholino oligomers (PMOs) for the induction of exon skipping of the human DMD gene","volume":"17","author":"Popplewell","year":"2009","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtn.2022.03.011_bib45","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1038\/labinvest.2016.88","article-title":"Immortalization of human normal and NF1 neurofibroma Schwann cells","volume":"96","author":"Li","year":"2016","journal-title":"Lab. Invest."},{"key":"10.1016\/j.omtn.2022.03.011_bib46","doi-asserted-by":"crossref","DOI":"10.3791\/52434-v","article-title":"Use of the Open Field Maze to measure locomotor and anxiety-like behavior in mice","author":"Seibenhener","year":"2015","journal-title":"J.\u00a0Vis. Exp."},{"key":"10.1016\/j.omtn.2022.03.011_bib47","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1038\/nprot.2006.170","article-title":"Assessing nest building in mice","volume":"1","author":"Deacon","year":"2006","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.omtn.2022.03.011_bib48","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1002\/humu.23929","article-title":"Clinical spectrum of individuals with pathogenic NF1 missense variants affecting p.Met1149, p.Arg1276 and p.Lys1423: genotype-phenotype study in neurofibromatosis type 1","volume":"41","author":"Koczkowska","year":"2019","journal-title":"Hum. Mutat."},{"key":"10.1016\/j.omtn.2022.03.011_bib49","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.ajhg.2017.12.001","article-title":"Genotype-phenotype correlation in NF1: evidence for a more severe phenotype associated with missense mutations affecting NF1 codons 844-848","volume":"102","author":"Koczkowska","year":"2018","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.omtn.2022.03.011_bib50","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1038\/s41436-018-0269-0","article-title":"Expanding the clinical phenotype of individuals with a 3-bp in-frame deletion of the NF1 gene (c.2970_2972del): an update of genotype-phenotype correlation","volume":"21","author":"Koczkowska","year":"2018","journal-title":"Genet. Med."},{"key":"10.1016\/j.omtn.2022.03.011_bib51","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1002\/humu.22832","article-title":"High incidence of noonan syndrome features including short stature and pulmonic stenosis in patients carrying NF1 missense mutations affecting p.Arg1809: genotype-phenotype correlation","volume":"36","author":"Rojnueangnit","year":"2015","journal-title":"Hum. Mutat."}],"container-title":["Molecular Therapy - Nucleic Acids"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2162253122000609?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2162253122000609?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T01:33:23Z","timestamp":1761874403000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2162253122000609"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6]]},"references-count":51,"alternative-id":["S2162253122000609"],"URL":"https:\/\/doi.org\/10.1016\/j.omtn.2022.03.011","relation":{},"ISSN":["2162-2531"],"issn-type":[{"value":"2162-2531","type":"print"}],"subject":[],"published":{"date-parts":[[2022,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeted exon skipping of NF1 exon 17 as a therapeutic for neurofibromatosis type I","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy - Nucleic Acids","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.omtn.2022.03.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors.","name":"copyright","label":"Copyright"}]}}